IMARC Group, a leading market research company, has recently releases report titled, “Anticoagulants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The study provides a detailed analysis of the industry, including the global anticoagulants market size, share, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights
How big is the anticoagulants market?
| Report Attributes | Details |
| Market Size in 2022 | US$ 37.4 Billion |
| Market Forecast in 2028 | US$ 67.0 Billion |
| Growth rate (2023 to 2028) | CAGR of 10.1% |
| Base Year of the Analysis | 2022 |
| Forecast Period | 2023-2028 |
What is anticoagulants?
Anticoagulants are specialized medicines that prevent blood clots and reduce the chances of developing severe medical conditions, such as strokes and heart attacks. They include warfarin, apixaban (eliquis), dabigatran (pradaxa), edoxaban (lixiana), and rivaroxaban (xarelto). They are widely used in the treatment of transient ischaemic attacks, atrial fibrillation and heart attacks, deep vein thrombosis (DVT), stroke, and pulmonary embolisms (PE). They aid in thinning blood and preventing blood cells called platelets from clumping together to form a clot and prolonging the clotting time. They come in different strengths and colors and are usually available in oral, such as tablets and capsules, and injectable forms. At present, anticoagulants are readily available at online stores, hospitals, and retail pharmacies across the globe.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/anticoagulants-market/requestsample
What are the growth prospects and trends in the anticoagulants industry?
The growing geriatric population and the increasing prevalence of cardiovascular disorders across the globe represent one of the key factors positively influencing the market. In addition, rising cases of pulmonary embolism (PE) on account of sedentary lifestyles and hectic work schedules are increasing the risk of heart-related diseases worldwide. This, along with the extended sitting, smoking, trauma, blood disorders, and autoimmune diseases can cause blood clotting in different parts of the body, which is catalyzing the demand for anticoagulants. The increasing prevalence of human immunodeficiency virus (HIV), Lyme disease, obesity, hepatitis C, and chronic inflammation are creating a favorable market outlook. Moreover, the increasing awareness about weight management and maintaining cardiovascular health among individuals and the importance of blood thinning is bolstering the market growth. Additionally, the easy availability of anticoagulants across offline and online distribution channels, coupled with the facilities of free doorstep delivery, lucrative deals and discounts, and secured payment gateways, are propelling the market growth. Besides this, the introduction of new anticoagulant agents that are orally administered and need less laboratory monitoring is contributing to the market growth. Furthermore, increasing investments by leading market players in research and development (R&D) activities for quality improvement of anticoagulants are creating a positive market outlook. Furthermore, favorable initiatives by non-profitable organizations (NPOs) to promote awareness about cardiovascular health are strengthening the growth of the market. Moreover, the growing partnerships between public health agencies and governments of various countries to prevent heart disease and strokes are catalyzing the demand for anticoagulants. Apart from this, the integration of advanced technologies, such as artificial intelligence (AI) on mobile devices for medication adherence in stroke patients undergoing anticoagulation therapy, is anticipated to drive the market.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Drug Class:
- Novel Oral Anticoagulants (NOACs)
- Heparin and Low Molecular Weight Heparin (LMWH)
- Vitamin K Antagonist
- Others
Breakup by Route of Administration:
- Oral Anticoagulant
- Injectable Anticoagulant
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
- Others
Breakup by Application:
- Atrial Fibrillation and Heart Attack
- Stroke
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Others
Breakup by Region:
- North America
- Asia-Pacific
- Europe
- Latin America
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Alexion Pharmaceuticals Inc
- Aspen Holdings
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Reddy’s Laboratories Ltd
- GlaxoSmithKline plc
- Johnson & Johnson Private Limited
- Pfizer Inc.
Ask Analyst for 10% Free Customized Report: https://www.imarcgroup.com/request?type=report&id=4360&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact us:
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Website: https://www.imarcgroup.com/
Follow us on Twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group